Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
作者信息
Wierda William G, Byrd John C, Davids Matthew S, Furman Richard R, Cheson Bruce D, Barr Paul M, Eradat Herbert, Heffner Leonard, Zhou Lang, Verdugo Maria, Potluri Jalaja, Choi Michael
机构信息
University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Medicine, College of Medicine, and Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH.
出版信息
Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27.
Abstract
摘要
相似文献
1
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.维奈托克用于接受一种以上B细胞受体途径抑制剂治疗后病情进展的慢性淋巴细胞白血病患者。
Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27.
2
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.维奈托克治疗复发/难治性慢性淋巴细胞白血病老年患者的疗效和安全性。
Br J Haematol. 2020 Mar;188(6):918-923. doi: 10.1111/bjh.16271. Epub 2019 Nov 4.
3
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
4
[Targeted treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的靶向治疗]
Ugeskr Laeger. 2014 Apr 7;176(15).
5
Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Venetoclax 治疗慢性淋巴细胞白血病患者肿瘤溶解综合征的实用管理。
Br J Haematol. 2020 Mar;188(6):844-851. doi: 10.1111/bjh.16345. Epub 2019 Dec 19.
6
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.接受维奈托克单药治疗的慢性淋巴细胞白血病患者凋亡机制中复发性基因组改变的鉴定
Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.
7
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.在 BCR 抑制剂治疗后复发的慢性淋巴细胞白血病患者中，venetoclax 单药治疗的疗效：英国范围内的分析。
Br J Haematol. 2019 May;185(4):656-669. doi: 10.1111/bjh.15802. Epub 2019 Feb 15.
8
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.维奈托克和伊布替尼用于复发/难治性慢性淋巴细胞白血病患者。
Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.
9
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.美国接受维奈托克治疗的慢性淋巴细胞白血病患者的真实世界结局和管理策略。
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
10
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications.NOTCH1激活对慢性淋巴细胞白血病中维奈托克敏感性的潜在影响：体外研究见解与临床意义
Br J Haematol. 2024 Oct;205(4):1389-1394. doi: 10.1111/bjh.19604. Epub 2024 Jun 21.
引用本文的文献
1
High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.高表达水平的 ROR1 和 ROR1 信号与慢性淋巴细胞白血病中 venetoclax 的耐药性相关。
Leukemia. 2022 Jun;36(6):1609-1618. doi: 10.1038/s41375-022-01543-y. Epub 2022 Apr 13.
2
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.2020年慢性淋巴细胞白血病的管理：聚焦布鲁顿酪氨酸激酶（BTK）和B细胞淋巴瘤-2（BCL-2）抑制剂的近期临床进展更新
Fac Rev. 2021 Feb 26;10:22. doi: 10.12703/r/10-22. eCollection 2021.
3
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.在不耐受 BTK 或 PI3Kδ 抑制剂治疗的 CLL 患者中，评估 umbralisib 安全性和疗效的 2 期研究。
Blood. 2021 May 20;137(20):2817-2826. doi: 10.1182/blood.2020007376.
4
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.克服慢性淋巴细胞白血病中的依鲁替尼耐药性
Cancers (Basel). 2019 Nov 21;11(12):1834. doi: 10.3390/cancers11121834.
本文引用的文献
1
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.维奈托克用于接受idelalisib 治疗期间或之后疾病进展的慢性淋巴细胞白血病患者。
Blood. 2018 Apr 12;131(15):1704-1711. doi: 10.1182/blood-2017-06-788133. Epub 2018 Jan 5.
2
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.依鲁替尼治疗后进展的慢性淋巴细胞白血病的维奈托克：多中心、开放标签、2 期试验的中期分析。
Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.
3
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.伊布替尼作为慢性淋巴细胞白血病患者的初始治疗方法。
N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
4
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.伊布替尼与奥法妥木单抗治疗既往治疗的慢性淋巴细胞白血病。
N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
5
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.依鲁替尼联合利妥昔单抗治疗复发慢性淋巴细胞白血病。
N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.
6
The tumor lysis syndrome.肿瘤溶解综合征
N Engl J Med. 2011 May 12;364(19):1844-54. doi: 10.1056/NEJMra0904569.
7
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.慢性淋巴细胞白血病诊断与治疗指南：慢性淋巴细胞白血病国际研讨会报告，更新美国国立癌症研究所工作组1996年指南
Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.
Zotero 插件